柳葉刀 (雜誌) - 维基百科，自由的百科全书
https://zh.wikipedia.org/wiki/柳葉刀_(雜誌)
Lopi mark this message contains personal perspective
｜originally written by Lopi
(1)確切的來說，刊登的不是英國《柳葉刀 The Lancet》期刊本身，而是附屬性的專業期刊《柳葉刀呼吸醫學 The Lancet Respiratory Medicine》月刊。原文可參考[2]
(2)文中對實驗結果的解釋 <Interpretation> 指出台灣高端疫苗 二期實驗結果安全，免疫反應良好，《這些數據支持高端疫苗進入 第三期保護效力實驗》。“MVC-COV1901 has a good safety profile and elicits promising immunogenicity responses. These data support MVC-COV1901 to enter phase 3 efficacy trials.”
(2)文中對實驗結果的解釋 <Interpretation> 指出台灣高端疫苗 二期實驗結果安全，免疫反應良好，《這些數據支持高端疫苗進入 第三期保護效力實驗》。“MVC-COV1901 has a good safety profile and elicits promising immunogenicity responses. These data support MVC-COV1901 to enter phase 3 efficacy trials.”
Opinion Sources
[1]https://zh.wikipedia.org/wiki/柳葉刀_(雜誌)[2]https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext
429 Internal Server Error
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.